Meeting
2022 ASCO Genitourinary Cancers Symposium
Impact of cytoreductive nephrectomy (CN) on survival in metastatic renal cell cancer (mRCC) treated with immune checkpoint inhibitors (ICI).
Authors
Stuthi Perimbeti
Roswell Park Cancer Center, Buffalo, NY
Stuthi Perimbeti , Changchuan Jiang , Lei Deng , Arya Roy , Keerthy Gopalakrishnan , Gurkamal S. Chatta , Saby George , Dharmesh Gopalakrishnan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 359)
DOI
10.1200/JCO.2022.40.6_suppl.359
Abstract #
359
Poster Bd #
L10
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era.
First Author: Joseph Miccio
Poster
2024 ASCO Genitourinary Cancers Symposium
The role of cytoreductive nephrectomy (CN) in the immune checkpoint inhibitor (ICI) era of metastatic renal cell carcinoma (mRCC): A systematic review and individual patient data (IPD) meta-analysis of 2319 patients.
First Author: Dimitrios Makrakis
Poster
2022 ASCO Genitourinary Cancers Symposium
SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer.
First Author: Ulka N. Vaishampayan
Poster
2022 ASCO Genitourinary Cancers Symposium
The role of cytoreductive nephrectomy and systemic therapy in the management of tumor thrombus in patients with metastatic renal cell carcinoma.
First Author: Abhenil Mittal